Comprehensive biomarker testing is essential for identifying patients with EGFR exon 20 insertion mutation+ mNSCLC

divider-mb

EGFR exon 20 insertion mutations are the third most prevalent primary EGFR mutation in mNSCLC, accounting for up to 9% of all EGFR mutations1,2

Compared with classical mutations, EGFR exon 20 insertion mutations reduce the size of the drug-binding pocket and affinity for most TKIs indicated for classical EGFR mutations.3*

*A763_Y764FQEA does not cause steric hindrance in the drug-binding pocket and has been shown to be sensitive to currently approved TKIs.

Use an FDA-approved NGS test to accurately identify patients with EGFR exon 20 insertion mutations who may benefit from treatment with RYBREVANT®.5

Mechanism of Disease

divider-mb
 

Learn what makes EGFR exon 20 insertion mutations different.1-3*

*A763_Y764FQEA does not cause steric hindrance in the drug-binding pocket and has been shown to be sensitive to currently approved TKIs.

EGFR, epidermal growth factor receptor; FDA, Food and Drug Administration; mNSCLC, metastatic non-small cell lung cancer; NGS, next-generation sequencing; TKI, tyrosine kinase inhibitor.

Explore

cnt-divider

efficacylogo

Efficacy

Explore the results from the
CHRYSALIS trial.

Learn more

safetylogo

Safety

Review the safety profile
of RYBREVANT®.

Learn more

dosinglogo

Dosing Guidelines

See the recommended dosage,
preparation and administration,
and dose modification information.

Learn more

register

Register for Updates

Sign up to receive the latest news and information about RYBREVANT® by completing the registration form.

References

1. Riess JW, Gandara DR, Frampton GM, et al. Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. J Thorac Oncol. 2018;13(10):1560-1568. doi:10.1016/j.jtho.2018.06.019

2. Arcila ME, Nafa K, Chaft JE, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013;12(2):220-229. doi:10.1158/1535-7163.MCT-12.0620

3. Robichaux JP, Elamin YY, Tan Z, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018;24(5):638-646. doi:10.1038/s41591-018-0007-9

4. Yasuda H, Park E, Yun CH, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer [published correction appears in Sci Transl Med. 2014 Feb 26;6(225):225er1]. Sci Transl Med. 2013;5(216):216ra177. doi:10.1126/scitranslmed.3007205

5. RYBREVANT® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.